What If GLP-1 Treatment Doesn't Work for You?

If Mounjaro, Wegovy or another GLP-1 medicine doesn't seem to be working for you, you are not alone, and it is rarely the whole story. In the first months, slow progress often reflects low starting doses. Beyond that, a minority of people genuinely lose less than expected, for reasons that range from missed doses and other medicines to health conditions and individual biology. NICE uses less than 5% weight loss after six months on the highest tolerated dose as a point to review treatment. This guide explains how response is judged, the common causes, and the options to discuss with a prescriber.

What "not working" means

People mean different things when they say a medicine isn't working. Being clear about which applies to you helps your prescriber decide what to do next.

What the evidence says about response rates

Clinical trials report the share of people who reached certain weight-loss thresholds. These figures help put individual experiences into context. They include people who stopped treatment early, so they reflect real-life drop-out as well as true non-response.

Put another way, roughly one in seven people on semaglutide and roughly one in ten on the highest dose of tirzepatide did not reach 5% weight loss in these trials.

Type 2 diabetes and response

People with type 2 diabetes generally lose less weight on GLP-1 medicines than people without diabetes, although they often see significant improvements in blood glucose.

If you have type 2 diabetes, it is worth adjusting expectations accordingly and focusing on wider health measures as well as weight. See our guide to GLP-1 medicines and type 2 diabetes.

How response is judged

Give titration time

Mounjaro starts at 2.5 mg weekly and Wegovy at 0.25 mg weekly. These starting doses are mainly there to help your body adjust and limit side effects; they aren't expected to produce the maximum effect. Doses are usually increased every four weeks, as tolerated. It can take several months to reach a dose that is likely to be effective for you. See our guides to Mounjaro dosing and Wegovy dosing.

NICE's review point

For NHS treatment, NICE technology appraisals TA875 (semaglutide) and TA1026 (tirzepatide) recommend considering stopping treatment if less than 5% of initial weight has been lost after six months on the highest tolerated dose. Private prescribers often use similar principles, although exact review points vary between services. The SmPC for each medicine also contains guidance for prescribers on ongoing treatment, so check the current version for exact wording.

This review point exists for good reasons. It helps avoid people continuing a medicine with side effects, risks and costs when it isn't helping them enough.

Look beyond the scales

Weight is the main measure, but not the only one. Your prescriber may also consider waist circumference, blood pressure, blood glucose, cholesterol and how you feel. Our guide to measuring progress beyond the scales explains these in more detail.

Common reasons a GLP-1 medicine may seem not to work

Before concluding that you're a non-responder, it's worth checking for practical issues. Many are easy to address.

Dose-related

• Still on a starting dose. Early doses are for tolerability.
• Dose held low because of side effects. Some people can't tolerate higher doses, which limits the effect.
• Repeated restarting. Gaps in treatment may lead to restarting at lower doses.

How the medicine is taken or stored

• Missed or delayed doses. Weekly injections need to be taken on a regular schedule. Our guide to Mounjaro missed doses explains the rules.
• Injection technique. Incorrect use of the pen could mean a dose isn't fully delivered. Ask your pharmacist or provider to check your technique.
• Storage problems. Injections must be stored according to the patient leaflet, usually in a fridge before first use and not frozen. Overheated or frozen pens may not work properly.
• Oral semaglutide timing. Wegovy tablets must be taken on an empty stomach with a small sip of water, followed by a waiting period. Taking them with food or other drinks can greatly reduce absorption.

Counterfeit or unregulated products

If you obtained a medicine without a proper prescription from a regulated pharmacy, it may not contain what it claims. The MHRA has seized large quantities of fake and unlicensed weight-loss medicines. A lack of effect, along with unusual side effects, can be a warning sign. See our guide to fake weight-loss jabs.

Other medicines

Some medicines can cause weight gain or make weight loss harder, including certain:

• Antidepressants and antipsychotics
• Steroid tablets
• Insulin and sulfonylureas used in diabetes
• Some anti-epileptic medicines

Don't stop any medicine without speaking to the prescriber responsible for it. There may be alternatives, but they need careful discussion.

Health conditions

Conditions that can affect weight include an underactive thyroid, Cushing's syndrome (rare), polycystic ovary syndrome, and hormonal changes around the menopause. Fluid retention from heart, kidney or liver problems can also mask fat loss. A GP can arrange checks if needed. See our guides to GLP-1 medicines and PCOS and GLP-1 medicines and the menopause.

Eating and drinking patterns

GLP-1 medicines reduce appetite but don't override every influence on eating. Regular alcohol, sugary drinks, frequent snacking and very calorie-dense foods can blunt their effect. Emotional eating or binge eating can also continue, and may need specific support. Our guide on what to eat on GLP-1 medication offers practical approaches.

Options a prescriber may discuss

If you've given treatment a fair trial and ruled out practical issues, your prescriber may suggest one or more of the following. These are decisions for your prescriber, based on your health and preferences.

Reviewing the dose

If you haven't reached the maximum licensed dose and are tolerating treatment, an increase may be considered. In January 2026 the MHRA approved a maximum Wegovy dose of up to 7.2 mg weekly for adults with obesity (BMI of 30 or more), based on the STEP UP trial; this may be an option for some people, though availability can vary. For Mounjaro, the maximum licensed dose is 15 mg weekly.

Trying a different medicine

In the SURMOUNT-5 trial, tirzepatide produced more average weight loss than semaglutide (around 20% versus 14% at 72 weeks). Some prescribers consider tirzepatide for people with a limited response to semaglutide. However, SURMOUNT-5 compared people starting each medicine, and there is limited trial evidence specifically in people who didn't respond to one medicine and then switched. Responding poorly to one GLP-1 medicine doesn't necessarily mean you will respond poorly to another, but a better response isn't certain either.

See our guides to switching from Wegovy to Mounjaro and Mounjaro vs Wegovy.

Adding structured support

Specialist weight management services, including those NHS services that prescribe under NICE guidance, combine medicine with dietetic, psychological and physical activity support. Some private providers offer similar support. Our guide to private versus NHS weight-loss treatment explains the differences.

Other medicines

Orlistat is another licensed weight-loss medicine that works differently, by reducing the absorption of fat from food. It generally produces smaller average weight loss than GLP-1 medicines, but may be suitable for some people. See our guide to orlistat vs GLP-1 medicines.

Bariatric surgery

For people with a higher BMI, particularly with weight-related conditions, bariatric surgery may be considered through NHS specialist services. Surgery tends to produce larger and more durable weight loss than current medicines, but has its own risks and requires lifelong follow-up. See our guide to GLP-1 medicines vs bariatric surgery.

Stopping treatment

If a medicine isn't helping enough, stopping it may be the right decision. This frees you from side effects, risks and costs that aren't giving you enough benefit. It is a choice to make with your prescriber, ideally with a plan for what comes next.

The cost side of non-response

If you're paying privately, continuing a medicine that isn't working has a financial as well as a health cost. Higher doses and some newer medicines can cost more, so it is worth discussing value openly with your prescriber. You can compare service options on our providers page and prices page; we don't quote prices in guides because they change.

Looking after yourself

A limited response can be frustrating and disappointing, especially when others seem to be doing well. Some points worth remembering:

• Response varies for biological reasons that you can't control.
• Modest weight loss can still bring health benefits, such as improved blood pressure or blood glucose.
• Health-promoting habits like good nutrition, activity, sleep and not smoking help regardless of weight.
• If you notice low mood, anxiety or difficult feelings about food or your body, please speak to your GP. Our guide to GLP-1 medicines and mental health may help.

More guides on this subject are in our plateau topic hub and the main guides library.

A practical checklist before your review

If you think your medicine isn't working, gathering a few details before your appointment helps your prescriber identify the cause. Consider noting:

This doesn't need to be perfect. Even a rough record helps.

Myths about non-response

"If it doesn't work for me, I must be doing something wrong"

Not necessarily. Even in carefully run trials where everyone received the same support, results varied widely. Some people lose less for biological reasons that aren't yet understood.

"I just need to try harder with diet"

Diet and activity matter, but GLP-1 medicines work mainly through appetite. If appetite hasn't changed on an effective dose, more willpower is unlikely to be the whole answer. A review with your prescriber is more useful than blaming yourself.

"A higher dose will definitely work"

Higher doses produced more weight loss on average in trials such as SURMOUNT-1 and STEP UP, but not everyone responds more at higher doses, and side effects may increase. Whether a dose increase is appropriate depends on your individual situation.

"A medicine from another source might work better"

Medicines obtained without a proper prescription from a regulated pharmacy may be counterfeit, contaminated or contain the wrong dose. The MHRA has warned repeatedly about these products. They carry real risks and are not a solution to a limited response.

How long to keep trying

There is no universal answer, but several principles guide prescribers:

• Allow enough time on an effective dose. Judging a medicine during the low-dose titration phase is usually premature.
• Use a clear review point. NICE's 5% at six months on the highest tolerated dose is a widely used benchmark, at least for NHS treatment.
• Balance benefits against burdens. Side effects, cost and practical demands all count.
• Don't continue indefinitely without benefit. If a medicine clearly isn't helping, stopping or changing approach is reasonable.

Your prescriber can help you weigh these factors and agree a plan with clear milestones.

Partial response: somewhere in between

Not everyone fits neatly into "responder" or "non-responder". Many people have a partial response: they lose some weight, perhaps 5% to 8%, but less than they hoped for or less than trial averages. This is a common situation, and it raises different questions from a complete lack of response.

For a partial responder, the discussion with a prescriber often focuses on:

• Whether the benefits are worthwhile. Even modest weight loss can improve blood pressure, blood glucose and joint pain.
• Whether there is room to increase the dose, if side effects allow.
• Whether practical factors are limiting the effect, such as missed doses or alcohol.
• Whether a different medicine might help more, bearing in mind the uncertainty about switching.
• The cost and burden of continuing compared with the benefits.

There is no single right answer. Some people are happy with a partial response, particularly if their health markers have improved. Others prefer to explore alternatives. Our guide to measuring progress beyond the scales can help you see the full picture.

When to speak to a professional

Speak to your prescriber, GP or pharmacist if:

• You have been on an effective dose for several months and lost little or no weight
• Your appetite hasn't changed at all on a meaningful dose
• You are unsure whether you are using your pen or taking your tablets correctly
• You started a new medicine and your weight has changed
• You have symptoms of a possible health condition, such as extreme tiredness, feeling cold, or changes in periods
• You obtained your medicine from a source that didn't require a proper consultation
• You feel low, anxious or are struggling with your relationship with food

Seek urgent medical help (NHS 111, or 999 in an emergency) if you have:

• Severe, persistent abdominal pain, which may spread to your back, with or without vomiting
• Repeated vomiting or diarrhoea with signs of dehydration
• Yellowing of the skin or eyes, or upper right abdominal pain with fever
• Signs of a severe allergic reaction, such as swelling of the face, lips or throat, or difficulty breathing
• Any unexpected or severe reaction to a product you suspect may be counterfeit

You can report suspected side effects or fake products through the MHRA Yellow Card scheme.